The biosimilar pipeline is starting to flow in the U.S. with the FDA receiving its second 351(k) biologic license application (BLA) in less than a month. Celltrion Inc. reported Monday that it has filed a BLA for its Remsima, a biosimilar of Janssen Biotech Inc.'s Remicade (infliximab).